JPH0523276B2 - - Google Patents

Info

Publication number: JPH0523276B2
Authority: JP; Japan
Prior art keywords: compound; present; cisplatin; water; drug
Prior art date: 1985-08-27
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

JP61152635A

Other languages

English (en)

Japanese (ja)

Other versions

JPS6345290A (ja

Inventor

Hiroyoshi Soto

Hiroshi Hayamizu

Yasuo Kuroda

Sumio Yoda

Katsutoshi Takahashi

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Nippon Kayaku Co Ltd

Original Assignee

Nippon Kayaku Co Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1985-08-27

Filing date

1986-07-01

Publication date

1993-04-02

1986-07-01 Application filed by Nippon Kayaku Co Ltd filed Critical Nippon Kayaku Co Ltd

1986-08-04 Priority to US06/893,108 priority Critical patent/US4737589A/en

1986-08-08 Priority to DE8686306162T priority patent/DE3667468D1/de

1986-08-08 Priority to CA000515594A priority patent/CA1258865A/en

1986-08-08 Priority to EP86306162A priority patent/EP0219936B1/en

1986-08-24 Priority to IL79819A priority patent/IL79819A0/xx

1986-08-25 Priority to AU61801/86A priority patent/AU595827B2/en

1986-08-26 Priority to KR1019860007083A priority patent/KR910009822B1/ko

1986-08-26 Priority to HU863688A priority patent/HU198302B/hu

1986-08-26 Priority to DK405986A priority patent/DK405986A/da

1986-08-26 Priority to CN 86105441 priority patent/CN1010314B/zh

1986-08-26 Priority to ES8601351A priority patent/ES2001586A6/es

1986-08-26 Priority to IE228186A priority patent/IE59225B1/en

1986-08-27 Priority to CS622986A priority patent/CS273618B2/cs

1987-08-19 Priority to US07/087,045 priority patent/US4864043A/en

1988-02-26 Publication of JPS6345290A publication Critical patent/JPS6345290A/ja

1989-06-27 Priority to US07/372,248 priority patent/US4921984A/en

1990-01-10 Priority to US07/464,671 priority patent/US5068376A/en

1992-10-07 Priority to JP4291914A priority patent/JPH05345792A/ja

1993-04-02 Publication of JPH0523276B2 publication Critical patent/JPH0523276B2/ja

Status Granted legal-status Critical Current

Links

BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims description 32
229910052697 platinum Inorganic materials 0.000 claims description 13
150000004985 diamines Chemical class 0.000 claims description 6
150000001875 compounds Chemical class 0.000 description 52
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 24
DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 21
229960004316 cisplatin Drugs 0.000 description 21
229940079593 drug Drugs 0.000 description 18
239000003814 drug Substances 0.000 description 18
210000004027 cell Anatomy 0.000 description 15
210000004881 tumor cell Anatomy 0.000 description 14
UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 12
230000000259 anti-tumor effect Effects 0.000 description 12
231100000417 nephrotoxicity Toxicity 0.000 description 12
241000699670 Mus sp. Species 0.000 description 11
239000007864 aqueous solution Substances 0.000 description 10
241000699666 Mus <mouse, genus> Species 0.000 description 9
230000003287 optical effect Effects 0.000 description 9
230000004083 survival effect Effects 0.000 description 9
238000012360 testing method Methods 0.000 description 9
238000006243 chemical reaction Methods 0.000 description 8
238000010998 test method Methods 0.000 description 8
238000000034 method Methods 0.000 description 7
238000003756 stirring Methods 0.000 description 7
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
239000013078 crystal Substances 0.000 description 6
150000003057 platinum Chemical class 0.000 description 6
SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 description 6
231100000419 toxicity Toxicity 0.000 description 6
230000001988 toxicity Effects 0.000 description 6
239000002246 antineoplastic agent Substances 0.000 description 5
230000037396 body weight Effects 0.000 description 5
CCQPAEQGAVNNIA-UHFFFAOYSA-N cyclobutane-1,1-dicarboxylic acid Chemical class OC(=O)C1(C(O)=O)CCC1 CCQPAEQGAVNNIA-UHFFFAOYSA-N 0.000 description 5
239000002895 emetic Substances 0.000 description 5
239000002504 physiological saline solution Substances 0.000 description 5
239000000243 solution Substances 0.000 description 5
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
231100000111 LD50 Toxicity 0.000 description 4
208000007093 Leukemia L1210 Diseases 0.000 description 4
238000004090 dissolution Methods 0.000 description 4
230000000694 effects Effects 0.000 description 4
238000000921 elemental analysis Methods 0.000 description 4
238000004992 fast atom bombardment mass spectroscopy Methods 0.000 description 4
GGQJPAQXCYUEKB-RXMQYKEDSA-N (2r)-2-methylbutane-1,4-diamine Chemical compound NC[C@H](C)CCN GGQJPAQXCYUEKB-RXMQYKEDSA-N 0.000 description 3
GGQJPAQXCYUEKB-UHFFFAOYSA-N 2-methylbutane-1,4-diamine Chemical compound NCC(C)CCN GGQJPAQXCYUEKB-UHFFFAOYSA-N 0.000 description 3
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 3
238000000862 absorption spectrum Methods 0.000 description 3
210000004369 blood Anatomy 0.000 description 3
239000008280 blood Substances 0.000 description 3
238000001914 filtration Methods 0.000 description 3
230000009036 growth inhibition Effects 0.000 description 3
230000005764 inhibitory process Effects 0.000 description 3
208000032839 leukemia Diseases 0.000 description 3
239000003446 ligand Substances 0.000 description 3
229910052700 potassium Inorganic materials 0.000 description 3
NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 3
230000035755 proliferation Effects 0.000 description 3
-1 silver halide Chemical class 0.000 description 3
229910001961 silver nitrate Inorganic materials 0.000 description 3
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
241001529936 Murinae Species 0.000 description 2
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
150000001412 amines Chemical class 0.000 description 2
125000004429 atom Chemical group 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
238000001647 drug administration Methods 0.000 description 2
239000000706 filtrate Substances 0.000 description 2
230000009422 growth inhibiting effect Effects 0.000 description 2
230000002401 inhibitory effect Effects 0.000 description 2
238000002347 injection Methods 0.000 description 2
239000007924 injection Substances 0.000 description 2
239000011591 potassium Substances 0.000 description 2
KIDHWZJUCRJVML-UHFFFAOYSA-N putrescine Chemical compound NCCCCN KIDHWZJUCRJVML-UHFFFAOYSA-N 0.000 description 2
229910052938 sodium sulfate Inorganic materials 0.000 description 2
235000011152 sodium sulphate Nutrition 0.000 description 2
238000003786 synthesis reaction Methods 0.000 description 2
YONLFQNRGZXBBF-ZIAGYGMSSA-N (2r,3r)-2,3-dibenzoyloxybutanedioic acid Chemical compound O([C@@H](C(=O)O)[C@@H](OC(=O)C=1C=CC=CC=1)C(O)=O)C(=O)C1=CC=CC=C1 YONLFQNRGZXBBF-ZIAGYGMSSA-N 0.000 description 1
YONLFQNRGZXBBF-KBPBESRZSA-N (2s,3s)-2,3-dibenzoyloxybutanedioic acid Chemical compound O([C@H](C(=O)O)[C@H](OC(=O)C=1C=CC=CC=1)C(O)=O)C(=O)C1=CC=CC=C1 YONLFQNRGZXBBF-KBPBESRZSA-N 0.000 description 1
SYTBZMRGLBWNTM-SNVBAGLBSA-N (R)-flurbiprofen Chemical compound FC1=CC([C@H](C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-SNVBAGLBSA-N 0.000 description 1
JKFYKCYQEWQPTM-UHFFFAOYSA-N 2-azaniumyl-2-(4-fluorophenyl)acetate Chemical compound OC(=O)C(N)C1=CC=C(F)C=C1 JKFYKCYQEWQPTM-UHFFFAOYSA-N 0.000 description 1
KMGUEILFFWDGFV-UHFFFAOYSA-N 2-benzoyl-2-benzoyloxy-3-hydroxybutanedioic acid Chemical compound C=1C=CC=CC=1C(=O)C(C(C(O)=O)O)(C(O)=O)OC(=O)C1=CC=CC=C1 KMGUEILFFWDGFV-UHFFFAOYSA-N 0.000 description 1
GAYWCADKXYCKCG-UHFFFAOYSA-N 5-pyridin-3-yl-1,2-dihydro-1,2,4-triazole-3-thione Chemical compound N1NC(=S)N=C1C1=CC=CN=C1 GAYWCADKXYCKCG-UHFFFAOYSA-N 0.000 description 1
108091003079 Bovine Serum Albumin Proteins 0.000 description 1
238000011740 C57BL/6 mouse Methods 0.000 description 1
201000009030 Carcinoma Diseases 0.000 description 1
206010009944 Colon cancer Diseases 0.000 description 1
201000008808 Fibrosarcoma Diseases 0.000 description 1
208000008342 Leukemia P388 Diseases 0.000 description 1
206010058467 Lung neoplasm malignant Diseases 0.000 description 1
VCUFZILGIRCDQQ-KRWDZBQOSA-N N-[[(5S)-2-oxo-3-(2-oxo-3H-1,3-benzoxazol-6-yl)-1,3-oxazolidin-5-yl]methyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C1O[C@H](CN1C1=CC2=C(NC(O2)=O)C=C1)CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F VCUFZILGIRCDQQ-KRWDZBQOSA-N 0.000 description 1
206010029155 Nephropathy toxic Diseases 0.000 description 1
239000012980 RPMI-1640 medium Substances 0.000 description 1
229910021612 Silver iodide Inorganic materials 0.000 description 1
PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 1
FHWFDHSUVNIGGR-UHFFFAOYSA-L [Pt](I)I.[K] Chemical compound [Pt](I)I.[K] FHWFDHSUVNIGGR-UHFFFAOYSA-L 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
239000002253 acid Substances 0.000 description 1
230000007059 acute toxicity Effects 0.000 description 1
231100000403 acute toxicity Toxicity 0.000 description 1
125000000217 alkyl group Chemical group 0.000 description 1
239000008346 aqueous phase Substances 0.000 description 1
SYEOWUNSTUDKGM-UHFFFAOYSA-N beta-methyladipic acid Natural products OC(=O)CC(C)CCC(O)=O SYEOWUNSTUDKGM-UHFFFAOYSA-N 0.000 description 1
229910052794 bromium Inorganic materials 0.000 description 1
239000003560 cancer drug Substances 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
125000004432 carbon atom Chemical group C* 0.000 description 1
150000001768 cations Chemical class 0.000 description 1
229910052801 chlorine Inorganic materials 0.000 description 1
208000029742 colonic neoplasm Diseases 0.000 description 1
238000001816 cooling Methods 0.000 description 1
125000004122 cyclic group Chemical group 0.000 description 1
230000018044 dehydration Effects 0.000 description 1
238000006297 dehydration reaction Methods 0.000 description 1
BNJBUDJCJPWKRQ-UHFFFAOYSA-H dipotassium;hexaiodoplatinum(2-) Chemical compound [K+].[K+].[I-].[I-].[I-].[I-].[I-].[I-].[Pt+4] BNJBUDJCJPWKRQ-UHFFFAOYSA-H 0.000 description 1
239000012153 distilled water Substances 0.000 description 1
239000002934 diuretic Substances 0.000 description 1
230000001882 diuretic effect Effects 0.000 description 1
230000001747 exhibiting effect Effects 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
238000000605 extraction Methods 0.000 description 1
239000012091 fetal bovine serum Substances 0.000 description 1
238000004817 gas chromatography Methods 0.000 description 1
231100000226 haematotoxicity Toxicity 0.000 description 1
125000005843 halogen group Chemical group 0.000 description 1
125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
238000002513 implantation Methods 0.000 description 1
239000011261 inert gas Substances 0.000 description 1
229910052740 iodine Inorganic materials 0.000 description 1
238000002955 isolation Methods 0.000 description 1
210000000265 leukocyte Anatomy 0.000 description 1
239000007788 liquid Substances 0.000 description 1
201000005202 lung cancer Diseases 0.000 description 1
208000020816 lung neoplasm Diseases 0.000 description 1
239000011259 mixed solution Substances 0.000 description 1
239000000203 mixture Substances 0.000 description 1
230000007694 nephrotoxicity Effects 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
125000004433 nitrogen atom Chemical group N* 0.000 description 1
239000012071 phase Substances 0.000 description 1
230000000704 physical effect Effects 0.000 description 1
238000000711 polarimetry Methods 0.000 description 1
230000008092 positive effect Effects 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
238000011084 recovery Methods 0.000 description 1
238000001953 recrystallisation Methods 0.000 description 1
238000011160 research Methods 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
239000012047 saturated solution Substances 0.000 description 1
238000000926 separation method Methods 0.000 description 1
229910052709 silver Inorganic materials 0.000 description 1
239000004332 silver Substances 0.000 description 1
229940045105 silver iodide Drugs 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000011734 sodium Substances 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
125000001424 substituent group Chemical group 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
230000004565 tumor cell growth Effects 0.000 description 1
238000005292 vacuum distillation Methods 0.000 description 1
238000005406 washing Methods 0.000 description 1

Landscapes

Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

JP61152635A 1985-08-27 1986-07-01 新規白金錯体 Granted JPS6345290A (ja)

Priority Applications (17)

Application Number	Priority Date	Filing Date	Title
US06/893,108 US4737589A (en)	1985-08-27	1986-08-04	Platinum Complexes
DE8686306162T DE3667468D1 (de)	1985-08-27	1986-08-08	Platinkomplexe.
CA000515594A CA1258865A (en)	1985-08-27	1986-08-08	Platinum complexes
EP86306162A EP0219936B1 (en)	1985-08-27	1986-08-08	Novel platinum complexes
IL79819A IL79819A0 (en)	1985-08-27	1986-08-24	Novel platinum complexes
AU61801/86A AU595827B2 (en)	1985-08-27	1986-08-25	Novel platinum complexes
CN 86105441 CN1010314B (zh)	1985-08-27	1986-08-26	新型的铂配合物生产方法
HU863688A HU198302B (en)	1985-08-27	1986-08-26	Process for producing new platine-komplexes and citostatice pharmaceuticalcompositions containing them as active components
DK405986A DK405986A (da)	1985-08-27	1986-08-26	Platinkomplekser
KR1019860007083A KR910009822B1 (ko)	1985-08-27	1986-08-26	백금 착화합물의 제조방법
ES8601351A ES2001586A6 (es)	1985-08-27	1986-08-26	Un procedimiento para producir un complejo de diamina platino (ii)
IE228186A IE59225B1 (en)	1985-08-27	1986-08-26	Novel platinum complexes
CS622986A CS273618B2 (en)	1985-08-27	1986-08-27	Method of diamino-platinous complex preparation
US07/087,045 US4864043A (en)	1985-08-27	1987-08-19	Platinum complexes
US07/372,248 US4921984A (en)	1985-08-27	1989-06-27	Novel platinum complexes
US07/464,671 US5068376A (en)	1985-08-27	1990-01-10	Novel platinum complexes
JP4291914A JPH05345792A (ja)	1986-07-01	1992-10-07	新規白金錯体

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
JP18771085		1985-08-27
JP60-187710		1985-08-27
JP61-26799		1986-02-12
JP61-26800		1986-02-12
JP61-94626		1986-04-25

Related Child Applications (1)

Application Number	Title	Priority Date	Filing Date
JP4291914A Division JPH05345792A (ja)	1986-07-01	1992-10-07	新規白金錯体

Publications (2)

Publication Number	Publication Date
JPS6345290A JPS6345290A (ja)	1988-02-26
JPH0523276B2 true JPH0523276B2 (it)	1993-04-02

Family

ID=16210812

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
JP61152635A Granted JPS6345290A (ja)	1985-08-27	1986-07-01	新規白金錯体
JP19813986A Pending JPS6345291A (ja)	1985-08-27	1986-08-26	ジアミン白金錯体の製造方法

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
JP19813986A Pending JPS6345291A (ja)	1985-08-27	1986-08-26	ジアミン白金錯体の製造方法

Country Status (2)

Country	Link
JP (2)	JPS6345290A (it)
ZA (1)	ZA866376B (it)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2008001851A1 (en) *	2006-06-28	2008-01-03	Ihi Corporation	Drug, drug induction device, magnetic detector and method of designing drug

Citations (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS5716895A (en) *	1980-07-05	1982-01-28	Otsuka Chem Co Ltd	Platinum 2 complex and antitumor agent containing the same as active principle
US4410544A (en) *	1978-07-06	1983-10-18	Nederlandse Centrale Organisatie voor Toegespastnatuurwetenschappeliukond erzoek	Platinum-diamine complexes, a method for the preparation of a medicine using such a platinum-diamine complex for the treatment of malignant tumor in mice

1986
- 1986-07-01 JP JP61152635A patent/JPS6345290A/ja active Granted
- 1986-08-22 ZA ZA866376A patent/ZA866376B/xx unknown
- 1986-08-26 JP JP19813986A patent/JPS6345291A/ja active Pending

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4410544A (en) *	1978-07-06	1983-10-18	Nederlandse Centrale Organisatie voor Toegespastnatuurwetenschappeliukond erzoek	Platinum-diamine complexes, a method for the preparation of a medicine using such a platinum-diamine complex for the treatment of malignant tumor in mice
JPS5716895A (en) *	1980-07-05	1982-01-28	Otsuka Chem Co Ltd	Platinum 2 complex and antitumor agent containing the same as active principle

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2008001851A1 (en) *	2006-06-28	2008-01-03	Ihi Corporation	Drug, drug induction device, magnetic detector and method of designing drug

Also Published As

Publication number	Publication date
JPS6345290A (ja)	1988-02-26
JPS6345291A (ja)	1988-02-26
ZA866376B (en)	1987-04-29

Publication	Publication Date	Title
EP0219936B1 (en)	1989-12-13	Novel platinum complexes
US4452812A (en)	1984-06-05	Organic complex of platinum, its preparation and its use for treating malignant tumors
CA1292749C (en)	1991-12-03	Platinum complexes
JPH036156B2 (it)	1991-01-29
KR890004350B1 (ko)	1989-10-31	글리콜산 백금 착체의 제조방법
EP0163316B1 (en)	1990-05-16	Platinum-intercalative complexes for the treatment of cancer
US4748254A (en)	1988-05-31	Mixed carboxylato platinum (II) complexes
CA2046313C (en)	1999-09-07	Platinum (ii) complex and agent for treating malignant tumor
JPH0523276B2 (it)	1993-04-02
EP0518645B1 (en)	1997-01-15	Platinum (II) complex and antitumor agent
JPWO2009090903A1 (ja)	2011-05-26	白金錯体化合物およびその利用
KR910009822B1 (ko)	1991-11-30	백금 착화합물의 제조방법
JPS61249993A (ja)	1986-11-07	新規有機白金錯体及びその製法
EP0308910A2 (en)	1989-03-29	Novel platinum complex
US5498780A (en)	1996-03-12	Platinum complex and malignant tumor treating drug containing the same
EP0310260A2 (en)	1989-04-05	Platinum complexes and their use as anti-tumor agents
EP0174114A1 (en)	1986-03-12	Platinum complexes of ascorbic acid and ascorbic acid analogs
JPH05345792A (ja)	1993-12-27	新規白金錯体
US5101054A (en)	1992-03-31	Novel fluorine-containing platinum complex
JPH02212497A (ja)	1990-08-23	新規白金錯体及びその製法
JPS63284190A (ja)	1988-11-21	新規白金錯体
JPS6230792A (ja)	1987-02-09	新規白金錯体
JPS61286396A (ja)	1986-12-16	新規白金錯体およびその用途
JPH049393A (ja)	1992-01-14	新規白金錯体およびそれを有効成分とする腫瘍治療剤
JPH0469393A (ja)	1992-03-04	新規白金錯体およびそれを有効成分とする腫瘍治療剤

JPH0523276B2 - - Google Patents

Info

Links

Landscapes

Priority Applications (17)

Applications Claiming Priority (5)

Related Child Applications (1)

Publications (2)

Family

ID=16210812

Family Applications (2)

Family Applications After (1)

Country Status (2)

Cited By (1)

Citations (2)

Patent Citations (2)

Cited By (1)

Also Published As

Similar Documents